Orchard Therapeutics

IPO

Homepage

Public · London, United Kingdom · Founded 2015 · $327.0M raised

Headquarters
London
Employees
51–200
Founded
2015
Business Model
B2B
Total Funding
$327.0M
Last Round
$34.0M Extension RoundJun 2023
Rounds
4
Type
Public

About

Founded in 2015, Orchard Therapeutics is a London-based gene therapy company and a Kyowa Kirin subsidiary since 2024, focused on ex vivo autologous hematopoietic stem cell (HSC) gene therapies for severe rare genetic diseases. The company's lead product Lenmeldy (atidarsagene autotemcel) received FDA approval for metachromatic leukodystrophy and is also approved in Europe as Libmeldy. Orchard has approximately 193 employees.

Summary

Orchard Therapeutics is a Biotech company based in London, United Kingdom, founded in 2015. It has raised $327.0M in total across 4 rounds, most recently a $34.0M Extension Round in Jun 2023. Investors include F-Prime Capital and RA Capital Management.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

AcquisitionAcquisition by Kyowa KirinJan 2024

Sign up to see all 6 events

Funding: Series A through Extension Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Orchard Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/orchard-therapeutics"><img src="https://indexed.vc/api/badge/company/orchard-therapeutics" alt="Orchard Therapeutics on Indexed.vc" width="260" height="76" /></a>